- Home
- SUUN vs INKT Comparison
SUUN vs INKT Comparison
Compare SUUN & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUUN | INKT |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.3M | 51.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SUUN | INKT |
|---|---|---|
| Price | $1.54 | $12.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 2.5M | 12.9K |
| Earning Date | 02-13-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $32,753,484.00 | N/A |
| Revenue This Year | $127.67 | N/A |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.23 | $4.56 |
| 52 Week High | $6.43 | $76.00 |
Technical Indicators
Market Signals| Indicator | SUUN | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 45.99 | 49.55 |
| Support Level | $1.45 | $11.28 |
| Resistance Level | $1.75 | $12.31 |
| Average True Range (ATR) | 0.17 | 0.49 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 16.03 | 58.02 |
Price Performance
Historical ComparisonAbout SUUN SolarBank Corporation
PowerBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.